Glucosamine sulfate, chondroitin sulfate.
Each film coated tablet contains: Glucosamine Sulphate 2 KCl 667 mg Equiv. to Glucosamine Sulphate 500 mg, Chondroitin Sulphate 400 mg.
Excipients/Inactive Ingredients: Microcrystalline cellulose, crospovidone, croscarmellose sodium, hydroxypropylcellulose, magnesium stearate, colloidal anhydrous silica.
Pharmacology: Glucosamine sulphate is stimulating proteoglycan synthesis, inhibiting the degradation and also stimulating the regeneration of experimentally-induced cartilage damage.
Chondroitin sulphate is increased joint glycoaminoglycan concentration and a subsequent enhancement of synovial fluid viscosity. Improvement in joint structure and function by increasing endogenous synthesis of hyaluronic acid and sulphated glycoaminoglycans and reducing breakdown of joint glycoaminoglycans subsequent to decreased collagenolytic activity and inhibition of enzymes which are capable of degrading existing joint glycoaminoglycans.
Pharmacokinetics: Glucosamine sulphate as oral administration, the peak was reached at the 9th hour after administration. The elimination half-life is 58 hours. The absolute oral bioavailability is 44%. The fecal excretion in 120 hour was 11.3% of the administered dose showing that at least 88.7% of the administered dose was absorbed through the gastrointestinal tract.
Chondroitin sulphate can be absorbed orally. The bioavailability of chondroitin sulphate ranges from 15% to 24% or the orally administered dose, 10% is in the form of chondroitin sulphate and 90% in the form of depolymerized derivatives with a lower molecular weight. Chondroitin sulphate is a slow-acting drug for the treatment of osteoarthritis, characterized by a slow onset of action, with a maximal effect being attained after several months of treatment with a carryover effect that persists after cessation of therapy.
Provide relief to sufferers of arthritis by reducing joint inflammation and relieving associated pain. It may help increase joint mobility by restoring cartilage tissue.
One tablet three times per day with meals.
No signs or symptoms of systemic toxicity of glucosamine sulphate and chondroitin sulphate have been reported.
Individuals with known hypersensitivity to any ingredients.
If the patient is pregnant or breast feeding, consult with the health care professional before using this product.
Not recommended taking Osteomin in pregnant women or breast-feeding women without consulting with the physician.
Adverse effects of glucosamine are minimal. There are reports of gastrointestinal symptoms, drowsiness, headache, and some skin rashes.
Should not take Osteomin concomitantly with warfarin.
Do not use this product if there are any significant changes in appearance of the tablets.
M01AX05 - glucosamine ; Belongs to the class of other non-steroidal antiinflammatory and antirheumatic products.
Sign Out
